Hematologic Diseases 
Welcome,         Profile    Billing    Logout  

16 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hematologic Diseases
PHCHBS-WD4070, NCT00718263: Efficacy and Safety of Nilotinib Patients With Newly Diagnosed CML - CP (Chronic Myelogenous Leukemia - Chronic Phase)

Checkmark In 2nd line CML chronic phase pts
Feb 2014 - Feb 2014: In 2nd line CML chronic phase pts
Active, not recruiting
3
90
Japan, US, Europe, RoW
Nilotinib, Imatinib
Novartis Pharmaceuticals
Myelogenous Leukemia, Chronic
10/18
10/18
Myeloma XI, NCT01554852 / 2009-010956-93: Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients

Checkmark From P3 Myeloma XI trial in NDDM at ASH 2016
Dec 2016 - Dec 2016: From P3 Myeloma XI trial in NDDM at ASH 2016
Checkmark ASH 2014
Nov 2014 - Nov 2014: ASH 2014
Active, not recruiting
3
4420
Europe
Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen, Revlimid (lenalidomide), Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen, Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen, Kyprolis (carfilzomib), Induction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimen, Induction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimen, Consolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimen, Velcade (bortezomib), Maintenance (intensive & non-intensive pathways) - lenalidomide maintenance, Maintenance (intensive & non-intensive pathways - protocol v5.0 only) - lenalidomide plus vorinostat maintenance, Zolinza (vorinostat), High dose melphalan therapy and autologous stem cell transplant (intensive pathway only)
University of Leeds, Celgene, Merck Sharp & Dohme LLC, Amgen
Multiple Myeloma
12/21
12/22
NCT01754402: Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma

Active, not recruiting
1/2
56
US
Bendamustine, Treanda, Bendeka, Pomalidomide, CC-4047, Pomalyst, Dexamethasone
Cristina Gasparetto, Celgene
Multiple Myeloma
12/16
01/25
NCT00302016 / 2005-001818-41: Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia

No Longer Available
N/A
US, Canada, Europe, RoW
AMN107
Novartis Pharmaceuticals
Chronic Myeloid Leukemia
11/08
 
NCT01892202: A Non-Interventional Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease Not on Dialysis

No Longer Available
N/A
RoW
Cohort
Hoffmann-La Roche
Anemia
02/11
02/11
NCT00413270: Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant

No Longer Available
N/A
Canada
nilotinib
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia
 
 
NCT01026376: An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS)

No Longer Available
N/A
RoW
decitabine
Janssen-Cilag Farmaceutica Ltda., Janssen Korea, Ltd., Korea
Myelodysplastic Syndromes
11/11
11/11
NCT01549548: Compassionate Use Ponatinib

No Longer Available
N/A
US
Ponatinib, AP24534
OHSU Knight Cancer Institute, Ariad Pharmaceuticals
Philadelphia Chromosome Positive (Ph+) Leukemias, Chronic Myeloid Leukemia
 
 
EAP, NCT00720603: This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant.

No Longer Available
N/A
US
Plerixafor, AMD3100, Mozobil
Genzyme, a Sanofi Company
Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma
 
 
NCT00999414: UARK 2009-32 Compassionate Use Study of Carfilzomib

No Longer Available
N/A
US
Carfilzomib
University of Arkansas, Onyx Therapeutics, Inc.
Multiple Myeloma
04/15
04/15
NCT02541643: Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma

No Longer Available
N/A
US
Elotuzumab, BMS-901608
Sundar Jagannath, Bristol-Myers Squibb
Multiple Myeloma
 
 
NCT00799539: A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients

No Longer Available
N/A
Canada
bortezomib, melphalan, prednisone
Janssen-Ortho Inc., Canada, Ortho Biotech Canada
Multiple Myeloma
 
 
NCT02204553: Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma

No Longer Available
N/A
US
Panobinostat
Novartis Pharmaceuticals
Multiple Myeloma
 
 
NCT02666209: Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma

No Longer Available
N/A
US
Ulocuplumab, BMS-936564, Lenalidomide, Revlimid, Bortezomib, Velcade, Dexamethasone, Decadron
Dana-Farber Cancer Institute, Bristol-Myers Squibb
Multiple Myeloma in Relapse, Multiple Myeloma
 
 
NCT02751554: PET Imaging of Patients Using 124I-PU-AD

Recruiting
N/A
10
US
124I-PU-AD, PET Scan, Blood draws
Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, Rockefeller University, Samus Therapeutics, Inc.
Solid Malignancy, Lymphoma, Multiple Myeloma, Alzheimer's Disease
04/18
08/18
NCT01730755: Ruxolitinib for Chuvash Polycythemia

No Longer Available
N/A
US
Ruxolitinib, Jakafi
Washington University School of Medicine, Incyte Corporation
Erythrocytosis, Familial, 2
 
 

Download Options